Zepos & Yannopoulos acted for the founding team of Purposeful in its strategic collaboration with PharOS, with the latter making a significant investment in the Greek startup and acquiring shares from existing shareholders, including Metavallon VC.
Purposeful aims to discover alternative uses for existing drugs using advanced artificial intelligence workflows, with a focus on finding therapies for rare diseases. During the last 5 years, the team has developed smart identification strategies for innovative pharmaceutical products targeting diseases like Fragile X Syndrome, Glioblastoma, Pitt-Hopkins Syndrome and Acrodysostosis.
Our firm assisted the founders of Purposeful on all key parameters of the transaction, including the negotiation of the transactional documentation. This is another testament of our commitment to promote innovation and the Greek startup ecosystem.
Our team was led by Stathis Orfanoudakis, senior associate, and supported by Artemis Bakagianni and Rania Koliouli, associates.